TY - JOUR
T1 - Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population
T2 - A report from the e-SELECT (Multi-center Post-Market Surveillance) registry
AU - Urban, Philip
AU - Abizaid, Alexandre
AU - Banning, Adrian
AU - Bartorelli, Antonio L.
AU - Baux, Ana Cebrian
AU - Davk, Vladimr
AU - Ellis, Stephen
AU - Gao, Runlin
AU - Holmes, David
AU - Jeong, Myung Ho
AU - Legrand, Victor
AU - Neumann, Franz Josef
AU - Nyakern, Maria
AU - Spaulding, Christian
AU - Worthley, Stephen
PY - 2011/3/29
Y1 - 2011/3/29
N2 - Objectives: The aim of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES). Background: Stent thrombosis and MB are major potential complications of drug-eluting stent implantation. Their relative incidence and predisposing factors among large populations treated worldwide are unclear. Methods: The SES were implanted in 15,147 patients who were entered in a multinational registry. We analyzed the incidence of: 1) definite and probable ST as defined by the Academic Research Consortium; and 2) MB, with the STEEPLE (Safety and efficacy of Enoxaparin in PCI) definition, together with their relation to dual antiplatelet therapy (DAPT) and to 1-year clinical outcomes. Results: The mean age of the sample was 62 ± 11 years, 30.4% were diabetic, 10% had a Charlson comorbidity index
AB - Objectives: The aim of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES). Background: Stent thrombosis and MB are major potential complications of drug-eluting stent implantation. Their relative incidence and predisposing factors among large populations treated worldwide are unclear. Methods: The SES were implanted in 15,147 patients who were entered in a multinational registry. We analyzed the incidence of: 1) definite and probable ST as defined by the Academic Research Consortium; and 2) MB, with the STEEPLE (Safety and efficacy of Enoxaparin in PCI) definition, together with their relation to dual antiplatelet therapy (DAPT) and to 1-year clinical outcomes. Results: The mean age of the sample was 62 ± 11 years, 30.4% were diabetic, 10% had a Charlson comorbidity index
KW - antithrombotic therapy
KW - bleeding complication
KW - coronary stent
KW - drug-eluting stent
KW - sirolimus-eluting stent
KW - stent thrombosis
UR - http://www.scopus.com/inward/record.url?scp=79952919635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952919635&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2010.11.028
DO - 10.1016/j.jacc.2010.11.028
M3 - Article
C2 - 21435513
AN - SCOPUS:79952919635
VL - 57
SP - 1445
EP - 1454
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
SN - 0735-1097
IS - 13
ER -